Valeant announces changes to executive management team
Christina Ackermann was named Executive Vice President and General Counsel.
Ms. Ackermann is Executive Vice President and General Counsel of Valeant Pharmaceuticals International, Inc.
Prior to joining Valeant Ms. Ackermann was part of the Novartis group of companies for the past 14 years, most recently serving as Senior Vice President, General Counsel for Alcon where she was responsible for the Legal, Intellectual Property and Compliance functions.
Prior to this, she served as Global Head, Legal and General Counsel at Sandoz, the generics division of Novartis, from 2007 to 2012.
She joined Novartis Pharma in 2002 as Head, Legal Technical Operations and Ophthalmics and assumed the role of Head Legal General Medicine in July 2005.
Before Novartis, Ms. Ackermann served in Associate General Counsel roles with Bristol Myers Squibb and DuPont Pharmaceuticals, as well as in private practice, where she focused on securities and mergers & acquisitions.
She has a Post Graduate Diploma in EC Competition Law from the University of London, U.K. and a Bachelor of Laws from Queen's University, Kingston, Canada.
Scott Hirsch Joins Valeant as Senior Vice President, Business Strategy and Communications
Valeant also announced that Scott Hirsch has joined the company as Senior Vice President, Business Strategy and Communications.
Mr. Hirsch is Senior Vice President, Business Strategy and Communications of Valeant Pharmaceuticals International, Inc.
Prior to joining Valeant, Mr. Hirsch was a Portfolio Manager at Citadel, Surveyor Capital overseeing equity investments and risk management decisions within the Health Care sector.
Prior to Citadel, he was the Lead Equity Research Analyst covering Specialty Pharmaceuticals and Global Generics for Credit Suisse.
Mr. Hirsch also has five years of experience in venture capital operating roles at JP Morgan Partners and Morgan Stanley Ventures portfolio companies, which included the development of health care marketing technologies subsequently acquired by WebMD.
He holds an MBA in Healthcare Management and Finance from Wharton and BFA from Rhode Island School of Design.
The company also announced a series of changes and promotions that expand the roles of key senior leaders.
Dr. Ari Kellen will serve as EVP and Company Group Chairman, and will lead the Bausch & Lomb business.
Anne Whitaker will also serve as EVP and Company Group Chairman, leading our branded pharmaceuticals businesses, including Salix, Dermatology, Dendreon, Orapharma and Women's Health, as well as Canada and U.S. Market Access and Commercial Services.
Tom Appio will be promoted to EVP and Company Group Chairman, and will lead all of Valeant's markets outside the United States and Canada.
In addition, Mr. Papa has expanded the Executive Committee, adding leaders from several key business and functional areas of the company, all of whom will report directly to him:
Dennis Asharin, SVP, Manufacturing and Supply Chain, who will assume responsibility for these functions globally.
Joe Gordon, SVP and General Manager, Consumer Business.
Barbara Purcell, General Manager, Neuro and Other, Generics and Obagi.
Tage Ramakrishna, M.D., Chief Medical Officer and President, R&D/Quality, who will continue to lead our R&D strategy and efforts across the company.
Kelly Webber, SVP, Human Resources, will now be responsible for HR globally. ■
What to read next
LATEST MOVES FROM Quebec
- Tecsys appoints Brian Cosgrove as CFO
- Amaya appoints Brian Kyle as CFO
- Amaya appoints Robin Chhabra as corporate development officer
- enGene appoints Theresa Podrebarac as CMO
- Air Canada chairman David I. Richardson to retire
More inside POST
COO, a chameleon in the company Leadership
Malaysia retains key policy rate Economy